Key Takeaways

• Vaccine buying group that helps medical practices and pharmacies navigate vaccine purchasing more efficiently
• CSL Seqirus is the only global vaccine manufacturer with flu as its core focus
• CSL Seqirus has delivered 100% of orders on-time and in-full by mid-October
• Flu vaccine pre-booking is expected to close on April 17, 2026
• ACIP and AAP both recommend annual flu vaccination for nearly all individuals ages 6 months and older.
• Children 6 months–8 years may need two doses the first season they’re vaccinated.
• Adults 65+ are recommended to receive an enhanced influenza vaccine (like FLUAD®), per ACIP.
• September–October is the ideal window, but vaccination continues throughout flu season.

Flu vaccine pre-booking for the 2026–2027 influenza season is now underway, making early planning more important than ever for medical practices and pharmacies. Ongoing supply considerations, evolving ACIP recommendations, and rising patient demand all make it essential to secure access to preferred flu vaccines early to support both clinical and operational success.

Pre-booking for the 2026–2027 flu season is currently open and will close on April 17, 2026. US Physicians’ Purchasing Group (USPPG) helps eligible vaccine providers access competitive pricing and reliable supply for CSL Seqirus influenza vaccines. CSL Seqirus flu vaccines include FLUCELVAX® and FLUAD®, by leveraging collective purchasing power.

Register Here for CSL Sequris Vaccine Discount

How USPPG Supports Flu Vaccine Purchasing

US Physicians’ Purchasing Group (USPPG) is a leading vaccine buying group that helps medical practices and pharmacies navigate vaccine purchasing more efficiently. By leveraging the collective volume of its nationwide membership, USPPG works directly with vaccine manufacturers and distributors to secure competitive pricing its members.

Although USPPG does not purchase vaccines directly, it plays a critical role in negotiating contract pricing for its members. Participating providers benefit from reduced pricing typically available only to larger organizations who buy in bulk. This approach helps independent practices and pharmacies remain competitive while continuing to deliver essential immunization services to their communities.

Why Vaccine Buying Groups Matter

Vaccine buying groups simplify the vaccine marketplace. Annual pre-booking programs, pricing structures, and allocation requirements often challenge providers—especially during high-demand flu seasons. By joining a purchasing group like USPPG, providers gain access to benefits that support predictability, affordability, and confidence in supply.

For flu vaccines in particular, early pre-booking allows practices to plan inventory, manage cash flow, and reduce the risk of in-season shortages. Buying group participation also gives providers clearer insight into manufacturer timelines, operational programs, and ordering strategies that align with their clinical needs.

CSL Seqirus: A Global Leader in Flu

CSL Seqirus stands on the front lines of public health as the only global vaccine manufacturer with flu as its core focus. With more than 100 years of expertise, this dedicated commitment to influenza enables CSL Seqirus to advance public health through enhanced flu vaccines that improve clinical outcomes for both children and adults.

CSL Seqirus operates the world’s largest cell-based flu manufacturing facility, allowing the company to meet demand even when supply conditions become unpredictable.

Enhanced Influenza Vaccine Portfolio

CSL Seqirus is the only vaccine manufacturer with a fully enhanced influenza vaccine portfolio, backed by both randomized clinical trial data and real-world evidence, that improves clinical outcomes for all eligible persons 6+ months.

Register For Free to Receive Contract Pricing

 

FLUCELVAX® (Influenza Vaccine) pre-filled syringe

 

FLUAD® (Adjuvanted Influenza Vaccine) pre-filled syringe

 

Operational Excellence

Season after season, CSL Seqirus extends its proven track record of supply reliability and efficiency. Over the past four seasons, CSL Seqirus has delivered 100% of orders on-time and in-full by mid-October—shipped two weeks ahead of original customer contract commitments.

FLUCELVAX also offers the operational benefit of a single SKU for all eligible individuals aged 6 months through 64 years, before transitioning to FLUAD for eligible adults aged 65 and older. Additionally, CSL Seqirus offers Order Now, Ship Now programs that provide expedited shipping on qualifying orders to support in-season needs.

Plan Ahead for the 2026–2027 Flu Season

With flu vaccine pre-booking expected to close on April 17, 2026, now is the time for providers to evaluate their influenza strategy for the upcoming season. Working with USPPG allows eligible members to take advantage of negotiated programs for CSL Seqirus vaccines while benefiting from the collective strength of a nationwide purchasing group.

Early planning helps ensure continuity of care, protects patient access to recommended vaccines, and supports smoother operations throughout flu season.

 

ACIP and AAP Influenza Vaccine Schedules

Both the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Pediatrics (AAP) publish annual guidance to help healthcare providers determine appropriate influenza vaccination timing, dosing, and product selection. These recommendations form the foundation for flu vaccination practices across the United States.

ACIP (Advisory Committee on Immunization Practices) Flu Vaccine Recommendations

Who should get vaccinated?

• Annual influenza vaccination is recommended for everyone aged ≥ 6 months who doesn’t have a medical contraindication. This is the longstanding guidance from ACIP.

Timing of vaccination:

• Vaccination is ideally offered September through October to ensure protection before flu season peaks. Vaccination should continue throughout the influenza season.

Children 6 months–8 years:

• Some children in this age group require two doses separated by at least 4 weeks during their first season of vaccination.

Adults ≥ 65 years:

• ACIP prefers high-dose, adjuvanted, or recombinant flu vaccines for adults ≥ 65 because of better immune response and protection in older adults. Fluad® is an example of an adjuvanted option recommended for this age group.

Pregnancy:

• Pregnant women can receive an age-appropriate inactivated or recombinant vaccine at any point in pregnancy.

Other points:

• ACIP generally does not rank different products as better than others for most age groups. The only exception is adults 65+ where specific enhanced vaccines are preferred.

AAP (American Academy of Pediatrics) Flu Vaccine Recommendations

Age & dosing:

• Children aged ≥ 6 months should receive annual influenza vaccination unless there’s a medical reason not to.
• Children aged 6 months–8 years who are being vaccinated for the first time (or who haven’t previously received two doses) should get two doses at least 4 weeks apart.

Timing:

• The AAP recommends vaccinating as soon as vaccine is available, especially for those requiring two doses, so they can complete the series before flu circulation peaks.
• Ideally, all pediatric vaccinations should be completed by the end of October for best community protection as flu viruses begin circulating.

Vaccine choice:

• Any licensed age-appropriate influenza vaccine may be used. Vaccination should not be delayed to wait for a specific product.

What This Means for Providers

Understanding ACIP and AAP influenza vaccine schedules is essential for effective vaccine planning, inventory management, and patient education. These recommendations help guide product selection, dosing strategies, and timing decisions throughout flu season.

By planning ahead and participating in flu vaccine pre-booking programs, providers can align with national immunization guidelines while helping ensure timely access to recommended influenza vaccines for their patient populations.

Register For Free Now